

DR N-PSDB: AAX86754.
 XX Modulator proteins that bind to and modulate the activity of the
 PT BRCA1 tumour suppressor gene product, useful for the treatment of
 PT ovarian and breast cancer
 XX
 PS Example 1; Fig 1; 35pp; English.
 XX
 CC The present sequence represents a modulator protein, that binds to and
 CC modulate the activity of the BRCA1 gene product (BRCA1). The BRCA1
 CC protein has been characterized as a tumour suppressor protein.
 CC Alterations in the amino acid sequence of BRCA1 causes breast and ovarian
 CC cancers by removing the controls on cell growth and proliferation.
 CC Research has shown that different regions on the BRCA1 molecule have
 CC different effects on cell growth and tumour suppression (e.g. full length
 CC truncated BRCA1 has no effect on breast cancer cell growth but will
 CC inhibit ovarian cancer cell growth). It has been suggested that different
 CC host cell factors (e.g. proteins) interact with different regions of the
 CC BRCA1 to control its function. The identification of these proteins
 CC (e.g. BRCA1MP) will facilitate the development of novel diagnostic
 CC methods and new therapeutics for identifying and treating cancers caused
 CC by changes in the expression or activity of BRCA1.
 XX
 SQ Sequence 469 AA;

Query Match 98.9%; Score 2357; DB 20; Length 469;
 Best Local Similarity 99.1%; Pred. No. 3.9e-184;
 Matches 465; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 MPRLALCTICSDFFDHSRDVAIHCGHTFHLQCLIQSFETAPSRTPCPCRIQVGRKTIIN 60
 DB 1 mprralcticsdffhsrdvaahcghthfhlqcliqwefetapscprcrlqvgkrtlin 60
 QY 61 KLFFDLAQEEENVLDREFLKNELDNVRNQLSQDKKRDQSVIITDLRDTLEENATVVS 120
 DB 61 klffdlageeenvldaeellkneidnvrnvaqlsqdkkrdsviitdlrdtleernatvvs 120
 QY 121 LQALGKAEMLCSTLRKQMKYLEQODDETQAOEAGRLRSKMKMTQEIELLQSOLPEV 180
 DB 121 lqalgaemlcstlrrkqmkyleqgdetkqageearrrlrrskmktmeqieilllqsqrpev 180
 QY 181 EEMIRDMGVGOSAVEQLAVYCVSLKKEYENIKRKASGEVADKLKRDLFSSRSKLQTVY 240
 DB 181 eemirdmvgosaveqlavycvslkkeyenikrkasgevadklrkrdlffssrsklqtvty 240
 QY 241 SELDQAKLELSAQDKDQSADEKIMSLSKKLTMLQETLNLPPVASETVDRVLESAPAVE 300
 DB 241 seldqaklelsaqdkdqsadkeimsllskltlmlqetlnlppvasetvdrvlesapave 300
 QY 301 VNLKLRPPSEFDDIDLNATFVDTPPARPSSSQHGYYEKLCLLEKSSHPIDVPKRICGP 360
 DB 301 vnllkrrpsfddidlnatfdvtparpsssqhgyyekllcllekshpiddvpkrikcgp 360
 QY 361 RKESQQLSLGQSCAGEPDEELVGAFFVRRALILGQKOPKRPRESSCSKDVRTGDCG 420
 DB 361 rkesqqlslgqscagepdeelvgafflvrnalilgqkoprresscskdvrtgdcg 420
 QY 421 GGRFKFTOPTDYVWIRPLPVKPKTKVKORVKTVPSTLFOAKLDTPLMS 469
 DB 421 ggrfkftoptdyvwirplpvkpktkvkorvktvpstlfoakldtplms 469

RESULT 2
 AAW37881
 ID AAW37881 standard; Protein; 469 AA.
 XX
 AC AAW37881;
 XX
 DT 28-AUG-1998 (first entry)
 XX
 DE BRCA1 modulator protein 091-21A31.
 XX

KW BRCA1 modulator protein; 091-21A31; breast cancer antigen 1;
 KW tumour suppressor protein; diagnosis; therapy; human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Domain 3..54
 FT /note= "zinc finger motif"
 FT Domain 229..255
 FT /note= "leucine zipper motif"
 XX
 PN W09810066-A1.
 XX
 PD 12-MAR-1998.
 XX
 PF 06-AUG-1997; 97W0-US13944.
 XX
 PR 04-SEP-1996; 96US-0025601.
 XX
 PA (ONYX-) ONYX PHARM INC.
 XX
 PI Ligenfelter C, Polakis P, Rubinfeld B, Vuong TT;
 XX WPI; 1998-193616/17.
 DR N-PSDB; AAV29062.
 XX
 PT Breast cancer antigen 1 modulator protein - useful for diagnosing
 PT diseases involving unwanted cell growth, e.g. breast cancer, and for
 PT producing therapeutics for treatment of such diseases
 XX
 PS Example 1; Fig 1; 73pp; English.
 XX
 CC This polypeptide comprises a 53 kDa BRCA1 modulator protein that
 CC binds to the tumour suppressor gene product BRCA1, and which is
 CC characterised by a zinc finger domain and a leucine zipper motif.
 CC Its amino acid sequence was deduced from the nucleotide sequence
 CC of a cDNA clone (see AAV29062), designated 091-21A31 (ATCC 98141),
 CC isolated from a HeLa cell cDNA library using a yeast two-hybrid
 CC assay. 3 cDNA clones (see also AAV29063-64) coding for BRCA1
 CC modulator proteins (see AAW37881-83) have been characterised. Vectors
 CC and host cells comprising the isolated nucleic acid sequences are
 CC claimed, as well as a process for producing BRCA1 modulator protein
 CC by culturing these host cells. BRCA1 modulator proteins and nucleic
 CC acids can be used to diagnose diseases involving unwanted cell
 CC growth, e.g. breast cancer, and to identify compounds that alter
 CC BRCA1 interaction with BRCA1 modulators for the treatment of such
 CC diseases.
 XX
 SQ Sequence 469 AA;

Query Match 98.6%; Score 2350; DB 19; Length 469;
 Best Local Similarity 98.9%; Pred. No. 1.5e-183;
 Matches 464; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 MPRLALCTICSDFFDHSRDVAIHCGHTFHLQCLIQSFETAPSRTPCPCRIQVGRKTIIN 60
 DB 1 mprralcticsdffhsrdvaahcghthfhlqcliqwefetapscprcrlqvgkrtlin 60
 QY 61 KLFFDLAQEEENVLDREFLKNELDNVRNQLSQDKKRDQSVIITDLRDTLEENATVVS 120
 DB 61 klffdlageeenvldaeellkneidnvrnvaqlsqdkkrdsviitdlrdtleernatvvs 120
 QY 121 LQALGKAEMLCSTLRKQMKYLEQODDETQAOEAGRLRSKMKMTQEIELLQSOLPEV 180
 DB 121 lqalgaemlcstlrrkqmkyleqgdetkqageearrrlrrskmktmeqieilllqsqrpev 180
 QY 181 EEMIRDMGVGOSAVEQLAVYCVSLKKEYENIKRKASGEVADKLKRDLFSSRSKLQTVY 240
 DB 181 eemirdmvgosaveqlavycvslkkeyenikrkasgevadklrkrdlffssrsklqtvty 240
 QY 241 SELDQAKLELSAQDKDQSADEKIMSLSKKLTMLQETLNLPPVASETVDRVLESAPAVE 300
 DB 241 seldqaklelsaqdkdqsadkeimsllskltlmlqetlnlppvasetvdrvlesapave 300

XX Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
XX Example 4; SEQ ID NO 2242; 10078bp; English.
XX
CC The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AA38642-AA42213) with nootropic,
CC immunosuppressant and cytoskeletal activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
CC
SQ Sequence 2663 AA:

Query Match 7.9%; Score 187.5; DB 22; Length 2663;
Best Local Similarity 25.1%; Pred. No. 7.9e-06;
Matches 93; Conservative 66; Mismatches 133; Indels 79; Gaps 18;

QY 55 KRITINKLFPDLAOGEEENVLDREFLNELDNVRAQLSQKKEK-RDSQVIITLRLDTLEE 113
DB 1632 kmavv-----etgkmcetehlkqefetqklnlenietenrltqj----lhenlee 1680
QY 114 RNATVVSIALQALGKAEMLCSTLKKOMKYLEQOQDET-----KQAOEENG-----RLRSKMT 165
DB 1681 mr-svkerddlrsv-----etlkverdqklnretlrdleqgeelkxvnmhmkqet 1736
QY 166 MEQIELLOSQLPVEBEMIRDMGVGOSAV-----EOLAVYCVSLKKEYENLKEARKA 217
DB 1737 idklrgivsektnetismgmqdlshndalkagdlkqgeelriahmhlkeqgetldkrlrgl 1796
QY 218 SGEVADKL---RKDLSSRSKLOTFVSELDQAKLELSAKDQASDK---ELMSLKKK- 270
DB 1797 vsektdklsmgmqdlensnaklqeklqeklkanehqltlclkdvnetqkvsemeqklkqj 1856
QY 271 -----LTMQ-ETLNPVPAASETVDL-----VLESPAIVEVNLKRRSFRDIT---- 314
DB 1857 kdqsltlstklelenlnlaqelhenlleemksvmkerdnlrveetlklerdqklesqek 1916
QY 315 --DUNATFDVDFPPARPSSSQH-----GYEKLK-----LEKSHSPIQDVPPK 355
DB 1917 ardlelqeklkt--arnlkskehketvdklreklsektlqdsldqkdkskdelq---kk 1971
QY 356 ICKGPKRESOL 366
DB 1972 igelqkkelqj 1982

RESULT 5
AA040883
ID AAA040883 standard; Protein; 2688 AA.
XX
XX AAA040883;
AC
XX
XX 22-OCT-2001 (first entry)
DE Human polypeptide SEQ ID NO 5814.
XX
XX Human; nootropic; immunosuppressant; cytoskeletal; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; Chemotactic;

KW Chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KM leukaemia.
XX
XX Homo sapiens.
OS
XX
XX WO200153312-A1.
PN
XX
XX 26-JUL-2001.
PD
XX
XX 26-DEC-2000; 2000MO-US34263.
PF
XX
XX 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
XX (HYSE-) HYSEQ INC.
PA
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
PI
XX
XX WPI: 2001-442253/47.
DR N-PSDB; AA160039.
DR
XX
XX Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
XX Example 2; SEQ ID NO 5814; 10078bp; English.
XX
CC The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AA38642-AA42213) with nootropic,
CC immunosuppressant and cytoskeletal activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC activation/inhibition activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
CC
SQ Sequence 2688 AA:

Query Match 7.9%; Score 187.5; DB 22; Length 2688;
Best Local Similarity 25.1%; Pred. No. 7.9e-06;
Matches 93; Conservative 66; Mismatches 133; Indels 79; Gaps 18;

QY 55 KRITINKLFPDLAOGEEENVLDREFLNELDNVRAQLSQKKEK-RDSQVIITLRLDTLEE 113
DB 1656 kmavv-----etgkmcetehlkqefetqklnlenietenrltqj----lhenlee 1704
QY 114 RNATVVSIALQALGKAEMLCSTLKKOMKYLEQOQDET-----KQAOEENG-----RLRSKMT 165
DB 1705 mr-svkerddlrsv-----etlkverdqklnretlrdleqgeelkxvnmhmkqet 1760
QY 166 MEQIELLOSQLPVEBEMIRDMGVGOSAV-----EOLAVYCVSLKKEYENLKEARKA 217
DB 1761 idklrgivsektnetismgmqdlshndalkagdlkqgeelriahmhlkeqgetldkrlrgl 1820
QY 218 SGEVADKL---RKDLSSRSKLOTFVSELDQAKLELSAKDQASDK---ELMSLKKK- 270
DB 1821 vsektdklsmgmqdlensnaklqeklqeklkanehqltlclkdvnetqkvsemeqklkqj 1880

OY 271 -----LTMLO-ETLNLPPVASETVDR-----VLESPAPVEVNLKLRPSFRDDI----- 314
 DB 1881 kqgsltlsktlelnlnlaqklhenleemksvmkerlnlrveetklrldqklesiqek 1940
 OY 315 --DLNATFPVDTPPARPSSQH-----GYEKLK-----LEKSHSPIQDVPK 355
 DB 1941 ardeiqgelkt--almkskenketvdklrksekltqdsldqkldkskdeiq---kk 1995
 OY 356 ICKGPKRESOL 366
 DB 1996 lqelqkkelqj 2006
 RESULT 6
 ABG06505
 ID ABG06505 standard; Protein; 2633 AA.
 AC ABG06505;
 XX
 DT 13-FEB-2002 (first entry)
 DE Novel human diagnostic protein #6496.
 XX
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX
 OS Homo sapiens.
 XX
 PN WO200175067-A2.
 XX
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001WO-US08631.
 XX
 PR 31-MAR-2000; 2000US-0540217.
 PR 23-AUG-2000; 2000US-0649167.
 XX
 XX (HYSE-) HYSEQ INC.
 PA Drmanac RT, Liu C, Tang YT;
 PI
 XX
 DR WPI; 2001-639362/73.
 DR N-PSDB; AAS70692.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity -
 XX
 PS Claim 20; SEQ ID NO 36864; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.

XX
 SQ Sequence 2633 AA;
 Query Match 7.7%; Score 184.5; DB 22; Length 2633;
 Best Local Similarity 24.4%; Pred. No. 1.4e-05;
 Matches 88; Conservative 66; Mismatches 135; Indels 71; Gaps 16;
 OY 55 KRITINKLFFDLAQBEEENVLDREFLNEDNVAQSLQSDKCR-RDSOYIIDLRLTLEE 113
 DB 1632 kmLavN-----etqkncelehlkeqetqklnlenitenlrllqj---lhenlee 1680
 OY 114 RNATVVSLOALGKAEMLCTKQKMYLEQODET-----KQAEPAQ-----RLRSKMT 165
 DB 1681 mr-svtkerddlrsv-----etlkverdqkenlrretltdrldkegelkvymhmkheqet 1736
 OY 166 MEQIELLLQSQLEPEVEEMIRDMGVQSAY-----EQLAVYCVSLKREYNELKPEARA 217
 DB 1737 idklrgivseektneismnqkdhensndal kagqlkqgeelrtriahmhkqgeetldkrlgi 1796
 OY 218 SCFVADKL---RKDLFSSRSKLOTVYSELDQAKLEKSAOKDQSDK---ELMSLKKR- 270
 DB 1797 vsektdklismqgkdhensnaklqeklqeklhqjlltkkdvneqkqvsemeqklkqj 1856
 OY 271 -----LTMLO-ETLNLPPVASETVDR-----VLESPAPVEVNLKLRPSFRDDIDLNA 318
 DB 1857 kqgsltlsktlelnlnlaqklhenleemksvmkerlnlrveetklrldqklesiqek 1916
 OY 319 TFDVDTPPARPSSQHGYEKLK-----LEKSHSPIQDVPKICKGPKRESOL 366
 DB 1917 ardeiqgelktcs-----ekisektlqdsldqkldkskdeiq---kkigelqkkelqj 1968
 RESULT 7
 AAB42919
 ID AAB42919 standard; Protein; 477 AA.
 XX
 AC AAB42919;
 XX
 DT 08-FEB-2001 (first entry)
 DE Human ORFX ORF2683 polypeptide sequence SEQ ID NO:5366.
 XX
 KW Human; open reading frame; ORFX: detection; cytostatic; hepatotropic;
 KW vulnerrary; antiposrotic; antiparkinsonian; nocrotropic; neuroprotective;
 KW anticonvulsant; osteopathic; antiarthritis; immunosuppressant; cardiant;
 KW immunostimulant; thrombolytic; coagulant; vasotropic; antidiabetic;
 KW hypotensive; dermatological; immunosuppressive; antinflammatory;
 KW antiviral; antibacterial; antifungal; antirheumatic; antihypoid;
 KW antianemic; gene therapy; cancer; proliferative disorder; hypertension;
 KW neurodegenerative disorder; osteoarthritis; graft vs host disease;
 KW cardiovascular disease; diabetes mellitus; hypothyroidism; SCID; AIDS;
 KW cholesterol ester storage; systemic lupus erythematosus; infection;
 KW severe combined immunodeficiency; malaria; autoimmune disorder; asthma;
 KW allergy; aplastic anaemia; nocturnal haemoglobinuria; burn; wound;
 KW bone damage; cartilage damage; antinflammatory disease; coagulation;
 KW thrombosis; contraceptive.
 XX
 OS Homo sapiens.
 XX
 PN WO200058473-A2.
 XX
 PD 05-OCT-2000.
 XX
 PF 31-MAR-2000; 2000WO-US08621.
 XX
 PR 31-MAR-1999; 99US-0127607.
 PR 02-APR-1999; 99US-0127636.
 PR 05-APR-1999; 99US-0127728.
 PR 30-MAR-2000; 2000US-0540763.
 XX
 PA (CURA-) CURAGEN CORP.

Query Match	Best Local Similarity	Score	DB	Length
Matches 84; Conservative 56; Mismatches 132; Indels 60; Gaps 14,	7.5%;	25.3%;	21;	477;
5	ALCTICSPDFSDHSROVAATHGCTHPLDLCIOSFETAPRS-----TCPOCRIOYG	54		
14	alcscicldyf-----tprvmtctgqhnfcraciqslswkargkdkgrrtkksgfpcpccemsp	70		
55	KRTII-NKLFEDLAQ--EEENVLDREFLKNELDNVRAQLSQDKDEKRDQSIVITDLRLTL	111		
71	gnllprllrlltkvaeaagqhpqjgkqdlqeghepklfcgkqdsp-----lcvcrear	125		
112	EEENMTVVSLOALGKAEMLCSTIKKQMKYLLDQOQDET--KQAQEPAGRLRSKMTMEI	169		
126	enrlhrvlpaaeevqgk1--kleeedmylrlqgllrtgqlaqareqslawqgkvkerr	182		
170	ELLLOSQLPREVEMIRDMGVGOSAEQOLVAVCVSLKKEVENLKEARKASGEVADKLKRD	229		
183	erlvle-----fekmlylv--eeegrlllqaleteeecastrlrev	222		
230	ESSRSKRLQIVSYELDOAKELKLSAQKDLQAD--KEIMSLKKLLTMLQETLMLPVYASGT	287		
223	acldtqghsl--elllllqleersltqgplqldmqkexpislrkhnv-----svgcpevapt	275		
288	VDRLVESPAPVEVNLKLRPSFRDDIDLNAT	319		
276	rprtvcrypgqlv---lr--gflcdvvpdat	302		
AAV31646	AAV31646 standard; Protein: 962 AA.			
AAV31646;				
02-NOV-1999	(first entry)			

DE		Human transport-associated protein-8 (TRANP-8).	
KX		Transport-associated protein; TRANP; nuclear pore; nuclear transport vesicle trafficking; cancer; cystic fibrosis; multidrug resistance;	
KW		hypercholesterolemia; diagnosis; treatment.	
KM			
XX		Homo sapiens.	
OS			
FH	Key	Location/Qualifiers	
FT	Modified-site	18 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	34 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	74 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	81 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	91 /note= "O-phosphorylated by tyrosine kinase"	
FT	Modified-site	101 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	101 /note= "N-glycosylated"	
FT	Modified-site	123 /note= "N-glycosylated"	
FT	Modified-site	129 /note= "N-glycosylated"	
FT	Modified-site	129 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	243 /note= "N-glycosylated"	
FT	Modified-site	336 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	410 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	451 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	451 /note= "N-glycosylated"	
FT	Modified-site	453 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	585 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	631 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	632 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	717 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	754 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	758 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	780 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	844 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	882 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	890 /note= "N-glycosylated"	
FT	Modified-site	902 /note= "O-phosphorylated by casein kinase II"	
FT	Modified-site	/note= "O-phosphorylated by casein kinase II"	
XX		WO99A1373-A2.	
PN			
PD	19-AUG-1999.		
XX			
PF	05-FEB-1999;	99WO-US02527.	
XX			
PR	11-FEB-1998;	98US-0021764.	
PA	(INCY-) INCYTE PHARM INC.		
XX			
P1	Au-Young J, Bandman O, Baughn MR,	Corley NC, Guegler KJ;	
XX	Hilliman JL, Lal P, Yue H;		
DR	WP1: 1999-508646/42.		
DR	N-PSDB: AAZ11738.		

XX Human TRAMP coding sequences, used to treat transport disorders and
PT cancer
XX
XX
PS Claim 1: Page 74-77; 87pp; English.
XX
CC This sequence represents human transport-associated protein-8 (TRAMP-8).
CC The DNA sequence was first identified in a human colon tissue
CC cDNA library. The full-length cDNA was derived from a series of
CC overlapping and/or extended cDNA sequences and is a consensus.
CC TRAMP-1 to 9 (AA131639-131647) are a novel group of proteins with
CC chemical and structural homology that are involved in molecular
CC transport. Various disorders are associated with defects in the transport
CC of molecules, either intracellularly or to the extracellular
CC environment. Examples of such disorders include cystic fibrosis,
CC multidrug resistance, hypercholesterolaemia and certain forms of diabetes
CC mellitus. Defective nuclear transport may play a role in cancer. For
CC example, the BRCA1 protein, associated with familial breast cancer, is
CC normally imported into the nucleus via nuclear pore complexes, but is
CC aberrantly located in the cytoplasm in breast cancer cells. In other
CC cancers, cells can secrete excessive amounts of hormones e.g. cancers of
CC the adrenal medulla can secrete excessive amounts of adrenaline and
CC noradrenaline, leading to hypertension. TRAMP is expressed in cancer
CC cells, and transport disorders result from either excessive or
CC insufficient molecular transport. Anti-TRAMP antibodies and nucleic acids
CC encoding TRAMP can be used as diagnostic tools for such disorders. TRAMP
CC antagonists can be used to treat or prevent a cancer associated with
CC increased TRAMP expression. Anti-TRAMP antibodies can be used directly
CC as an antagonist or as a targeting mechanism for drugs. Alternatively,
CC a TRAMP antisense nucleotide can be used to treat cancers. A TRAMP
CC agonist or expression vector may be used to treat a disorder caused by
CC reduced transport of biologically active molecules.
XX
SQ Sequence 962 AA:

Query Match 7.5%; Score 178; DB 20; Length 962;
Best Local Similarity 20.4%; Pred. No. 1.1e-05;
Matches 76; Conservative 62; Mismatches 92; Indels 142; Gaps 11;

OY 52 QVGRKRIITIKLFP-----DLAQBENVLDREFLK--NELDNV--RAQLS 91
DB 571 rlgkenfiekfkgfshkelyrsasqkqpnfpeseymfihetkivkelegvltkaiyk 630
OY 92 OKDKERDSOV-----IIDTLRDLERNATVVSLOQALG----RAEMCSITLKQ 138
DB 631 sseedkkeeavkktleqhndivhykmmiregdqlaeelrqvstlkqneqlqtavtqg 650
OY 139 MKYLEQOODE-----TKQAQ-----EAGRLRSKMKMTQIEILLQ 174
DB 691 vsqieqghkdqynllkldqgkdnghgsysegagmqnlgpeelsrllreelckrnqellq 750
OY 175 SOLPEVEEIRDMGVGQSA-----VEOLAVYCVSLK----- 205
DB 751 sqktekmdlsmkmsqtsqtnegsaivsardseqvaellkqelatlksqjnsqveitk 810
OY 206 -----KEYENLKERRKASGEV 221
DB 811 lqtekbellqkteafaskevsveggetilatkttdvegrrlsallqetckelmeikalsee 870
OY 222 ADLRRKDLFSSRSKLTQTVYSELDQAKLELKSQAKD-----LOSADKEIMSLKKRLTML 274
DB 871 rtaikqelidsnstiaqlqtekdckleletidskqegdllylladqgkllstknklkd 930
OY 275 QETLNLPPVASE 286
DB 931 gh-----pveee 937

RESULT 9
AAM79969
ID AAM79969 standard; Protein; 533 AA.
XX

AC AAM79969;
XX
DT 06-NOV-2001 (first entry)
XX
XX Human protein SEQ ID NO 3615.
DE
XX
XX Human: cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;
KW nervous system disorder; arthritis; inflammation.
XX
XX Homo sapiens.
OS
PN MO200157190-A2.
PD
XX
XX 09-AUG-2001.
PF
XX 05-FEB-2001; 2001WO-US04098.
PR 03-FEB-2000; 2000US-0496914.
PR 27-APR-2000; 2000US-0560875.
PR 20-JUN-2000; 2000US-0598075.
PR 19-JUL-2000; 2000US-0620325.
PR 01-SEP-2000; 2000US-0654936.
PR 15-SEP-2000; 2000US-0663561.
PR 20-OCT-2000; 2000US-0693325.
PR 30-NOV-2000; 2000US-0728422.
XX
XX (HYSE-) HYSEQ INC.
PA
XX
XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
PI Zhang QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
XX
XX WPI: 2001-476283/51.
DR N-PSDB: AAK53102.
XX
XX Nucleic acids encoding polypeptides with cytokine-like activities,
PT useful in diagnosis and gene therapy -
XX
XX
XX Claim 20; Page 397; 6221pp; English.
PS
XX
XX The invention relates to polynucleotides (AAK51456-AAK53435) and the
CC encoded polypeptides (AAM78323-AAW80302) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
CC (AAM80020) are omitted as the relevant pages from the sequence listing
CC were missing at the time of publication.
XX
SQ Sequence 533 AA:

Query Match 7.3%; Score 174.5; DB 22; Length 533;
Best Local Similarity 20.2%; Pred. No. 9.7e-06;
Matches 86; Conservative 84; Mismatches 155; Indels 101; Gaps 15;

OY 30 HLOCLIQSEFTAPSRFCPOCRIGV-----KRTIIN--KLFPDLAQE----- 70
DB 15 hievikesl-takeqraallqtevdaalrlrleeekmlnkktkqigdmeeekygtggeh 73
OY 71 --ENVLDRE-----FLKNELDNVRALQSOKDKKRSQVYIIDTLRDLERNATVVSLOQ 123
DB 74 dlkdmdlvkerkvnvlgkklkneilqegldrdekqmsalrkerkvsldgdtntdaltlle 133
OY 124 ALGKAEMLCSTLKKQMKYLEQOODETFKQAQEEAGRLRSKMKMTQIEILLQSQLPVEEM 183

```

Db 134 alaeekertlerlk-----egrdrderekegetdnykkdklkdlekexsllqgdlseskeas 187
QY 184 IRDMGVQGS-----AVDQLAVYCY----SLAKEVENLKEARAKAGEV 221
Db 188 Ildlkheasslaassgllkddarlktlalealeqkkeecikmesgllkkaheaalear-aaapem 246
QY 222 ADK---LRKDLFSSRSKLTQVYSELDQAKLELKSAGKDLSADKEISL-----267
Db 247 sdrlqherelttrykdeesskagaevdrllellkevenekhdckkialeelsrkykdq 306
QY 268 -----KKKLTMLQETL---NLPPVASETVDRVLVESPAVEYNLKLRRP 308
Db 307 nkkvanlkhekqeyekkkksaqmleearrednlndssqglqdsllrkkgdrleel-----ee 361
QY 309 SFRDDIDLNTFPV---DTTPARPSSOHGYEKLCEKSHSPIQDYPKIKCKGPR----361
Db 362 altesvqltaeremvlagaesartnaekyveellmanekvkqelasmkaklssltqgsiae 421
QY 362 KESQLS 367
Db 422 kethlt 427

RESULT 10
ABG03671
ID ABG03671 standard; protein; 463 AA.
AC ABG03671;
XX
XX 13-FEB-2002 (first entry)
DE
XX Novel human diagnostic protein #3662.
KW Human: chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.
XX
XX Homo sapiens.
OS
XX PN MO200175067-A2.
XX PD 11-OCT-2001.
XX PF 30-MAR-2001; 2001WO-US08631.
XX PR 31-MAR-2000; 2000US-0540217.
XX PR 23-AUG-2000; 2000US-0649167.
XX PA (HYSE-) HYSEQ INC.
XX PI Dmanac RT, Liu C, Tang YT;
XX DR WPI, 2001-639362/73.
XX DR N-PSDB; AAS67858.
XX
XX New isolated polynucleotide and encoded polypeptides, useful in
XX diagnostics, forensics, gene mapping, identification of mutations
XX responsible for genetic disorders or other traits and to assess
XX biodiversity -
XX
XX Claim 20: SEQ ID NO 34030; 103bp; English.
XX
XX The invention relates to isolated polynucleotide (I) and
XX polypeptide (II) sequences. (I) is useful as hybridisation probes,
XX polymerase chain reaction (PCR) primers, oligomers, and for chromosome
XX and gene mapping, and in recombinant production of (II). The
XX polynucleotides are also used in diagnostics as expressed sequence tags
XX for identifying expressed genes. (I) is useful in gene therapy techniques
XX to restore normal activity of (II) or to treat disease states involving
XX (II). (II) is useful for generating antibodies against it, detecting or
XX quantitating a polypeptide in tissue, as molecular weight markers and as
XX a food supplement. (II) and its binding partners are useful in medical
XX imaging of sites expressing (II). (I) and (II) are useful for treating

```

```

CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_sequences.
XX
XX Sequence 463 AA:
XX
XX Query Match 7.3%; Score 174; DB 22; Length 463;
XX Best Local Similarity 24.2%; Pred. No. 8.7e-06;
XX Matches 78; Conservative 52; Mismatches 130; Indels 62; Gaps 11;
XX
XX 29 FHLQCLIOSFETAPSRCTPCRCRIQVCKRTIYNKLFDLAOEENVLDRFLKNELDNVRA 88
XX Db 126 felqalleerka-----yrnqvsest--kqlqvlaqwgqrfhldtenlreqkdnela 176
XX
XX QY 89 QLSOKDKERDSOYII-DTLRDTLEERNATVSLQALGR--AEM-----LCSTLKKQMK 140
XX Db 177 sardelhsardemwlvnqaaakvaserdtldaslqgeelkvrseleerwkaaseykevt 236
XX
XX QY 141 YL-----EEOQODETKQAOEAGRLRSKMKTME-----QIELLOSQLEPEVE 161
XX Db 237 slqnsfqlrcqgcedqgreasrlqgeleklrfeualetechs}krenvllsselqrg 236
XX
XX QY 182 -----EMIRDMGVQGSAAVEQLAVYCVSLAKEVENLKEARAKAGEVADLRKDLF 230
XX Db 297 kelhnsqkqsltsdtsllqmsrkelengyslkeghlidsadlklklskaengakdvq 356
XX
XX QY 231 SSRSKLTQVYSELDQAKLELKSAGKDLSADKEISLKKKLTMLQETLNLPPVASETVDR 230
XX Db 357 keyektqtlvsel---klktemtegeqksltdelkqcknklkirekgnpsll-----407
XX
XX QY 291 LVLESPAPVEYNLKLRRPSFRD 312
XX Db 408 -----qvpvartlrp1--pgifpd 423
XX
XX RESULT 11
XX AAB69070
XX ID AAB69070 standard; protein; 1374 AA.
XX AC AAB69070;
XX
XX DT 19-APR-2001 (first entry)
XX
XX DE Human male enhanced antigen-2 (MEA-2) protein sequence SEQ ID NO:2.
XX KW Human: male enhanced antigen-2; MEA-2; identification; spermatogenesis;
XX spermatogenesis disease; chromosome marker; pancreatic cancer.
XX
XX OS Homo sapiens.
XX PN JP2000316580-A.
XX PD 21-NOV-2000.
XX PF 30-APR-1999; 99JP-0125196.
XX PR 30-APR-1999; 99JP-0125196.
XX PA (ITOH-) ITO HAM KK.
XX DR WPI: 2001-128256/14.
XX DR N-PSDB; AAF32508.
XX
XX A new protein, human male-enhanced antigen-2, useful for detecting
XX spermatogenesis diseases -

```


XX Claim 1: Page 12-15; 21pp; Japanese.

CC The present sequence represents the human male enhanced antigen-2
 CC (ME4-2). The present invention also described an antibody specific for
 CC the ME4-2 protein. The antibody can be used for the identification of a
 CC gene causing diseases related to spermatogenesis. The ME4-2 nucleotide
 CC sequence is useful as a chromosome marker, and in the detection of
 CC pancreatic cancer.

XX Sequence 1374 AA:

Query Match 7.2%; Score 172.5; DB 22; Length 1374;
 Best Local Similarity 24.7%; Pred. No. 5.2e-05;
 Matches 72; Conservative 57; Mismatches 120; Indels 43; Gaps 9;

QY 35 IOSFETAPSTPCQCRIOVGKRTIINKLFPDLAOEENVLDFEFLKNEID-----NVRA 88
 DB 1084 Ikrleesnkklalelehekgklcglgsnaal-rehnsiletalakreadlvglnlvqga 1142
 QY 89 OLSOKDKERDSQVIIDTLBTDLEERNATVYSLOALGKAEMLCSTIKKQKMYLEOQDE 148
 DB 1143 vlgtrkeedqgmhivqajqaslekekevnsikeqvaaakeaghnrtmfkaaslelse 1202
 QY 149 TR-----QAOEAGRLRSKMTME-----QIEL-----LLOSQLPEVEEM 183
 DB 1203 vkkelqakehlyvklgaeadddlqregkhsqelafqgaelaearaqqlilqkql---deq 1259
 QY 184 IRPMGCGQSAVEQOLAVYCVSLKREYENLKEARKASGEVADKLRRDFFSSRSKLTQVYSEL 243
 DB 1260 lskpqyngqemelnkewdckereisqlkqqlalteqg---rkelleglqqlgnvksel 1316
 QY 244 DOKLEKSKOXLOLSADKREIMSLKKL-TMLDET-----INLPPVASETYDR 290
 DB 1317 emeqedlsmtkckfmlgakvselknmklclqngqklklrtgaaekvlr 1368

RESULT 12

ID ABB58673 standard; Protein; 1456 AA.

AC ABB58673;
 DT 26-MAR-2002 (first entry)

DE Drosophila melanogaster polypeptide SEQ ID NO 2811.

KW Drosophila; developmental biology; cell signalling; insecticide;
 KW pharmaceutical.

OS Drosophila melanogaster.

PN WO200171042-A2.

PD 27-SEP-2001.

PF 23-MAR-2001; 2001WO-US09231.

PR 23-MAR-2000; 2000US-191637P.

PR 11-JUL-2000; 2000US-0614150.

PA (PEKE) PE CORP NY.

PI Venter JC, Adams M, Li PWD, Myers EW;

DR WPI; 2001-656860/75.

DR N-PSDB; ABL02776.

XX New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 XX

PS Disclosure; SEQ ID NO 2811; 21pp + Sequence Listing; English.

CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (AB101840-AB16175) and the encoded proteins
 CC (AB57737-AB72072).

CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.

XX Sequence 1456 AA:

Query Match 7.2%; Score 170.5; DB 22; Length 1456;
 Best Local Similarity 20.1%; Pred. No. 8.3e-05;
 Matches 116; Conservative 97; Mismatches 202; Indels 163; Gaps 22;

QY 15 DHRSDVAIIR---CGHFFHLCLOSFETAPSTPCQCRIOVGKRTIINKLFPDLAOEE 71
 DB 55 dygrhavlveslcaeehymlqtdveem-----rarleeknrllkktgltl---g 104
 QY 72 NVLDREFLKNELDNVRAQLSQDKERDSQVIIDTLBTDLEERN----- 115
 DB 105 tvgermrntselcelkdmdikarkisvgrkhenledllikekndydmarrlsamqah 164
 QY 116 -----ATVVSLOALGKAEMLCSTLKQKMYLEOQDETQ-----AQEE 155
 DB 165 hsssegaltaleaigdkkqmagqlrdqrdraehkeqcerdlherevadkiklraae 224
 QY 156 AGRLRSKMK-----TMEQIELL---QSOL-----PEVEEMRDGCGQSAVEQOLAVYCVSL 204
 DB 225 veklqtrlevatererleiklaasqelgkskaelekatcengrsadwestkqrlarl 284
 QY 205 KREYENLKEARKAS-----GEVADKLRRDFFSSRSKLTQVYSELDOA 246
 DB 285 elenerlkhdlersqtlfttmttsqelidageradkasaalrrtqaelrtvqsdaera 344
 QY 247 KLELKSADKDLQSDADKEIMSLKKRLTML---OETLNLPPVASETYDRVLESPPAVEVN 302
 DB 345 reeaanaqekleksgsyvrlkaklenagqeslqgelekagysvrlhaddrafsev 404
 QY 303 LKLRPSFRDDIDLNATFDVDTPPARPSSQHGVEKL---CLEKSHSPI---QDVPKIC 357
 DB 405 ekikeemerqatlg-----ksqlqh---eklqnsldkaqevdhldkldkac 450
 QY 358 KGPRLK-----ESQLSLG-GQSCAGEPDEELVGAFPIVRNAI-----IG 395
 DB 451 tenrilylekekltydmdlsgldkalqgaamqgerelisdtdtrlekltkqyqlg 510
 QY 396 QKQPKR-----PRSESSCS-----KDVVRTGFDGLGRTKFTQPTDVMIR 436
 DB 511 rldqkerdqfdeletlkeresaeqltlmkaardreamqtdlevlker----- 557
 QY 437 PLPVKPKTKYKQVRVK-----TVPSLFOAKLDTFLMS 469
 DB 558 ---yekshaiqkqlmerdavelellkekiklkaiya 592

RESULT 13

ID ABB59033 standard; Protein; 951 AA.

AC ABB59033;

DT 26-MAR-2002 (first entry)

DE Drosophila melanogaster polypeptide SEQ ID NO 3891.

KW Drosophila; developmental biology; cell signalling; insecticide;

KM pharmaceutical.
 XX Drosophila melanogaster.
 OS
 XX
 PN WO200171042-A2.
 XX
 PD 27-SEP-2001.
 XX
 PD 23-MAR-2001; 2001WO-US09231.
 XX
 PF 23-MAR-2000; 2000US-191637P.
 XX
 PR 11-JUL-2000; 2000US-0614150.
 PR
 XX
 PA (PEKE) PE CORP NY.
 XX
 PI Venter JC, Adams M, Li PMD, Myers EW;
 XX
 DR WPI, 2001-656860/75.
 DR N-PSDB; ABL03136.
 XX
 XX
 PT New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 PS
 PS
 PS Disclosure; SEQ ID NO 3891; 21pp + Sequence listing; English.
 XX
 CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (AB16176-AB130511), expressed DNA
 CC sequences (AB101840-AB16175) and the encoded proteins
 CC (AB857737-AB872072).
 CC
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences.
 CC
 XX
 XX Sequence 951 AA;

Query Match 7.18; Score 170; DB 22; Length 951;
 Best Local Similarity 20.9%; Pred. No. 5e-05;
 Matches 94; Conservative 91; Mismatches 157; Indels 108; Gaps 19;
 OY 72 NVLDR-EFLKNELDNVRAOQSOKDKERKDSQVIID---TLRDLEFRNMTVYSLOQALG 126
 DB 333 npldrvghikqelytralgnlknkreevrlekllleerngelrvlrdgengslvq1-elIn 391
 OY 127 KAEMLCSTLKQMKYLBQODETKQAOEAGRLRSKMTMEIQLLOSQLPEVEEMIRD 186
 DB 392 egkm---rlenkvykamqgeleeqghrsqsdvhsqslnsivaedalrerkqgee---- 444
 OY 187 MCGQGSAVEQOLAVYCVSLKREYENLKARK--ASGEVADKLR-----KDLSSRS 234
 DB 445 -----die1kqgnes1grnyd1sgenrg1lrretcad1rlelherk11llrsgseve 498
 OY 235 KLOTVSELOQAKLELSAQKDLQSDAD--KEIMSLKKKLTMOETLMPVASTVTRIV 292
 DB 499 r1k1ysd1ctdes1gylr1k1resd1lke1qdrq1natvq1n1jaemkseel1k11 558
 OY 293 LESPAPVEVMIK-LRPSFRD-----DIDLNATFDV 322
 DB 559 etek1sher1dqlr1qse1ek1reava1vakessensck1es1aelt1k1e1q11k1qnv 618
 OY 323 DTPPARP-SSSQHGTYEKLCLEKSHSPIQVPPKICKGPKRESQSLSGGSCAGEPDEEL 381
 DB 619 nsmaqek1kelenh-----alegskn1gaemqek1elnsnkqdel1s-----dlker 663
 OY 382 VGAFPIFVRNALIGOKQPKPRSSSSSKDVVRGFGDLGRKTFIOTPTDVTMIRLPVK 441
 DB 664 akqfdeay1r-----qgeehkqgnkctp-----spksnsvpsd-----psp-k 700

OY 442 PKTK-----VKORVRVKTVPSPLEQAKIDTF 466
 DB 701 elctgnr1rlleg1rvr-demak1faaelkrf 729

RESULT 14
 AAM78985
 ID AAM78985 standard; Protein; 484 AA.
 XX
 AC AAM78985;
 XX
 DT 06-NOV-2001 (first entry)
 DT
 XX
 DE Human protein SEQ ID NO 1647.
 XX
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell; growth factor; hematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorder; arthritis; inflammation.
 XX
 OS Homo sapiens.
 XX
 PN WO200157190-A2.
 PD
 PD 09-AUG-2001.
 XX
 PF 05-FEB-2001; 2001WO-US04098.
 XX
 PR 03-FEB-2000; 2000US-0496914.
 PR 27-APR-2000; 2000US-0560875.
 PR 20-JUN-2000; 2000US-0598075.
 PR 19-JUL-2000; 2000US-0620325.
 PR 01-SEP-2000; 2000US-0654936.
 PR 15-SEP-2000; 2000US-0663561.
 PR 20-OCT-2000; 2000US-0693325.
 PR 30-NOV-2000; 2000US-0728422.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
 PI Zhao QA, Wang D, Zhang J, Ren F, Chen R, Wang ZW;
 PI Xue AJ, Yang Y, Wejrtman T, Goodrich R;
 DR WPI; 2001-476283/51.
 DR N-PSDB; AAK52118.
 XX
 PT Nucleic acids encoding polypeptides with cytokine-like activities,
 PT useful in diagnosis and gene therapy -
 PS
 PS Claim 20: Page 3984-3985; 6221pp; English.
 XX
 CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
 CC encoded polypeptides (AAM78323-AAAM0302) that exhibit activity elating to
 CC cytokine, cell proliferation or cell differentiation or which may induce
 CC production of other cytokines in other cell populations. The
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
 CC peptide therapy. The polypeptides have various cytokine-like activities,
 CC e.g. stem cell growth factor activity, hematopoiesis regulating
 CC activity, tissue growth factor activity, immunomodulatory activity and
 CC activin/inhibin activity and may be useful in the diagnosis and/or
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
 CC inflammation.
 CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
 CC (AAM0020) are omitted as the relevant pages from the sequence listing
 CC were missing at the time of publication.
 XX
 SO Sequence 484 AA;

Query Match 7.18; Score 169.5; DB 22; Length 484;
 Best Local Similarity 20.3%; Pred. No. 2.2e-05;
 Matches 75; Conservative 72; Mismatches 143; Indels 79; Gaps 11;

Oy	61	KLFPLDAGEENVLDREFLNKELNDVNRALSDKDKRDSQVILIDRLRDLERNAATVVS	120
Oy	27	kmldvkerkvnlqk-----klenlgeqlrdkekqmsalkekvkslqgdttntdalt	81
Oy	121	LOQALGKAEMLCSTLKKQKMYLEOODDEFKQAOEAGRLRSKKTKTMOETELLQSOLEPV	180
Oy	82	leelaakeertlerlk-----eqtrderekgeeyidanykkdklkdakevsllygdalsek	135
Oy	181	EMIRDMGVGOS-----AVEQLAVYCV---SLKREYENLKEARKAS	218
Oy	136	easllldlehaslassgllkkgdsrlkltlealeqkkeecelimesqllkthalear-as	194
Oy	219	GEVADK---LKKDLFSSRSKSLQTVYSELDQAKLELKSAAKDQASDKETMSL-----	267
Oy	195	pemsdrighleretlrykdseskaqevgrlllellkevenekdkdklaeelslrgy	254
Oy	268	-----KKKLTMOETL-----NLPVASETVDRILVLESAPAVENVLKL	305
Oy	235	kdgqkkanllkheqevkkksqgmleearrrrednlnndssqllqdslyrkddrleel---	310
Oy	306	RPRSFDDIDLNATFDV---DTPPARSSSOHGUYEKLCLSEKSHSPIDVPKRTCKGPR-	361
Oy	311	cealresvqtaeacemvjaagesartnnekqveellmamekvkgelesmkakslstqgs	369
Oy	362	---KESQLS 367	
Oy	370	laekethlt 378	
RESULT	15		
ID	ABB61144		
xx	ABB61144	standard; Protein; 1690 AA.	
xx	ABB61144;		
xx	26-MAR-2002	(first entry)	
xx	Drosophila melanogaster	polypeptide SEQ ID NO 10224.	
xx	Drosophila	developmental biology; cell signalling; insecticide;	
xx	pharmaceutical.		
xx	Drosophila	melanogaster.	
xx	WO200171042-A2.		
xx	27-SEP-2001.		
xx	23-MAR-2001;	2001WO-US09231.	
xx	23-MAR-2000;	2000US-191637P.	
xx	11-JUL-2000;	2000US-0614150.	
xx	(PEKE)	PE CORP NY.	
xx	Venter JC,	Adams M, Li PMD, Myers EW;	
xx	WPI:	2001-656860/75.	
xx	N-PSDB;	ABL05247.	
xx	New isolated	nucleic acid detection reagent for detecting 1000 or more	
xx	genes from	Drosophila and for elucidating cell signalling and cell-cell	
xx	interactions -		
xx	Disclosure:	SEQ ID NO 10224; 21pp + Sequence Listing; English.	
xx	The invention	relates to an isolated nucleic acid detection reagent	
xx	capable of	detecting 1000 or more genes from Drosophila. The invention is	
xx	useful in	developmental biology and in elucidating cell signalling and	
xx	cell-cell	interactions in higher eukaryotes for the development of	
xx	insecticides,	therapeutics and pharmaceutical drugs. The invention	
xx	discloses	genomic DNA sequences (ABL16176-ABL30511), expressed DNA	
xx	sequences	(ABL01840-ABL16175) and the encoded proteins	

CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pat_sequences.

SQ Sequence 1690 AA;

Query Match	7.1%;	Score 169;	DB 22;	Length 1690;
Best Local Similarity	20.7%;	Pred. No. 0.00014;		
Matches	83;	Conservative	84;	Mismatches 158;
			Indels	76;
			Gaps	13;

Qy	50	RIQVAKRTIINKLFEPDLAOEENVLDRFLKNE--LDNVRALQSLCKDKKEDKDSOYIIDTL	107
Db	724	q4lekesieqgl--alkqneledfqkkyeseevhlqelkaqntqkdfelivesgeslkl	781
Qy	108	RTTLEERNATVYSLQOALGKAEMLCSTLKQKQK-VLEOQODFTKQAOEAGHLSRKMTM	166
Db	702	qqqlqgkcltlyhneklgaal-----eellkeketlikeqelqglqksaesesaikvv	834
Qy	167	E-QIEILLQSQLOPEVEENIRDMGVGQSAVEQDLAVYCVSLKKEYE-----	209
Db	835	qyqleqlqgqaaasgeegsktvaklhndelsqksgaeetqselkctqsnleakskqlaea	894
Qy	210	--NLKEARKASEVAD---KLKRDLFSSRSKIQITYSELDOAKLELKSQKDLGADMEI	264
Db	895	ngslseeaakshgllleqklklkseygetqaalschtsdvestkqlaanaalekvkey	954
Qy	265	MSLKKLLMLQDTLMLPPVASETVDRVLVESPAPEVN--LKLRRPSPRDDI-----DLN	317
Db	955	aesreaesdlqdkv-----keitdtlnaelqaer:sssalhtktsktsdelaqhkelt	1008
Qy	318	ATFVDV-----DTPPARPSSQHGYEKLCLCEKSHSPIQDVPKRTIC	357
Db	1009	skadawsgemlqkekelqelqrlqdsqdsqtklkaegerkeksftees---lknlgeevt	1065
Qy	338	KGPRESQLSLGGQSCAGEPDEELVGAFPIFYRNAILGQKQ	398
Db	1066	kaktenlelstgttclikdlgerle-----ltnaelqpkhe	1100
RESULT 16			
ID	ABB61173	ID ABB61173 standard; Protein: 1690 AA.	
xx	AC	ABB61173;	
xx	DT	26-MAR-2002 (first entry)	
xx	DE	Drosophila melanogaster polypeptide SEQ ID NO 10311.	
xx	KM	Drosophila: developmental biology; cell signalling; insecticide; pharmaceutical.	
xx	OS	Drosophila melanogaster.	
xx	PN	WO200171042-A2.	
xx	PD	27-SEP-2001.	
xx	PF	23-MAR-2001; 2001WO-US09231.	
xx	PR	23-MAR-2000; 2000US-191637P.	
xx	PR	11-JUL-2000; 2000US-0614150.	
xx	PA	(PEKE) PE CORP NY.	
xx	PI	Venter JC, Adams M, Li PWD, Myers EW;	
xx	DR	WPI; 2001-656860/75.	
xx	DR	N-PSDB; ABL05276.	
xx	PT	New isolated nucleic acid detection reagent for detecting 1000 or more	

XX 26-JAN-1999.
XX
XX 04-JUL-1997; 97JP-0179490.
XX PF
XX 04-JUL-1997; 97JP-0179490.
XX PR
XX (ITOH-) ITO HAM KK.
XX PA
XX WPI: 1999-160962/14.
XX DR N-PSDB; AAX04132.
XX
XX Regulation of spermatogenesis using Mea-2 gene information - using
PT anti-sense oligo- or polynucleotide(s), used for production of
PT contraceptives
XX
XX Claim 4; page 8-12; 27pp; Japanese.
XX
XX The present sequence represents mouse male enhanced antigen 2 (Mea-2).
CC The present invention describes the regulation of spermatogenesis by
CC using Mea-2 information. A non-human living organism can have its
CC spermatogenesis inhibited by breakage of the whole or part of the Mea-2
CC gene. Also described are: (1) the creation of the spermatogenesis-
CC inhibited organism; (2) a drug composition containing an oligonucleotide
CC or polynucleotide containing base sequences that pair with at least part
CC of the Mea-2 gene and are able to inhibit the expression of Mea-2 gene;
CC and (3) the creation of an aimed gene-possessing organism using the
CC spermatogenesis inhibited organism. The organism is useful for producing
CC contraceptive drugs.
XX
XX Sequence 1325 AA;
SQ

Query Match 7.0%; Score 168; DB 20; Length 1325;
Best Local Similarity 20.6%; Pred. No. 0.00012;

Matches 77; Conservative 65; Mismatches 130; Indels 102; Gaps 13;

QY 68 QEEENVLDREFLNEDL-----NVRALQSOKDKERDSQVITDITLRTLEERNATVSL 121
DB 966 remslletalakraedlvglnqvgavlgqrkeedtrgmklvgalslekemvnsl 1025
QY 122 QQALGKA-----EMLCSTLKKKKYLEEQ----QDET 149
DB 1026 keemaarleaighnrhfkfaatleevkkelqakehlvgltgaevdelqdgkhsgei 1085
QY 150 KQAEAGRLRSKMKMTMEQELLQSQLPVEEMIRDMGVSADVQLAVYCYSLKKEYE 209
DB 1086 agqtelaearlqg-----llqkkl--degmsqqrptsgqemedlkwelqkqereid 1135
QY 210 NLKEARKASGEVADKLRLKDLFSRSKLTQVYSELDOAKLELKSQOKDLQSGADKEIMSLKK 269
DB 1136 sltqgldileggg---kkelqgtqqlgtlkselamvgedlsestqydkfkmlqakvaelkn 1192
QY 270 KL-TMLDET-----LMLP--PVASETVDRVLVESPA 297
DB 1193 nmktllqgnqqlklldlrqgaakkkepkgesnsspatpklipdcyppaslleellpppa 1252
QY 298 ----PVEVNLKLRPSFRDID-LNATFDVTPPARPSSQOHYREKLCLEKSHSPIQDV 352
DB 1253 vskeplk-lhnnclqglkqgmdslgrqmehtltlvheslsswagveaapehah----- 1305
QY 353 PKKICGPKRESOL 366
DB 1306 -----prgdtkl 1312

RESULT 19
AAU01768
ID AAU01768 standard; protein; 934 AA.
XX
AC AAU01768;
XX
DT 18-JUL-2001 (first entry)

XX
DE Human secreted protein #47.
XX

KW Human; secreted protein; immunogen; antibody; diagnosis;
KW rheumatoid arthritis; hyperproliferative disorder; neoplasm;
KW cardiovascular disorder; cerebrovascular disorder; cerebral ischaemia;
KW angiogenesis; Alzheimer's disease; bacterial infection; viral infection;
KW fungal infection; corneal infection; wound healing; cell culture;
KW epithelial cell proliferation; skin ageing; transplantation;
KW tissue regeneration; chemotaxis; food additive.
XX
XX Homo sapiens.
XX
XX WO200123546-A1.
XX
XX 05-APR-2001.
XX
XX 26-SEP-2000; 2000WO-US26323.
XX
XX 27-SEP-1999; 99US-0155805.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Ruben S, Komatsoulis GA;
XX
XX WPI: 2001-266150/27.
XX
XX N-PSDB; AAS02399.
XX
XX Disclosure; page 460-463; 494pp; English.

PT Nucleic acids encoding 37 human secreted polypeptides, useful for
PT preventing, diagnosing and/or treating e.g. cancers, Parkinson's
PT disease and diabetic retinopathy -
XX
XX

PS The sequence represents a human secreted protein of the invention. The
CC polynucleotides, polypeptides and antibodies raised against them are used
CC to prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. The
CC polynucleotides and antibodies are also used in diagnosing a pathological
CC condition or susceptibility to a pathological condition. The antibodies
CC can also be used in alleviating symptoms associated with the disorders
CC and in diagnostic immunoassays e.g. radioimmunoassays or enzyme linked
CC immunosorbent assays (ELISA). Disorders which are diagnosed or treated
CC include autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC infections caused by bacteria, viruses and fungi and ocular disorders
CC e.g. corneal infection. The polypeptides can also be used to aid wound
CC healing and epithelial cell proliferation, to prevent skin aging due to
CC sunburn, to maintain organs before transplantation, for supporting cell
CC culture of primary tissues, to regenerate tissues and in chemotaxis. The
CC polypeptides can also be used as a food additive or preservative to
CC increase or decrease storage capabilities.
XX
XX Sequence 934 AA;
SQ

Query Match 7.0%; Score 167.5; DB 22; Length 934;
Best Local Similarity 22.8%; Pred. No. 7.9e-05;

Matches 91; Conservative 82; Mismatches 139; Indels 87; Gaps 21;

QY 24 HCGHTF-HIOCLQSFETASRTCPQCRIOVGKRTIINKLFFPLADBEENVLDREF-LKN 81
DB 433 hlnhsishkeqllqetf-----relqyrdsndtllsaneaml--lekrlqjhdhkaaler 485
QY 82 ELDNVRAOLQSOKDKERDSQVIT-----DTLRTLEERNATVSLQOALG----KAEM 130
DB 486 aldekfsaleekekelnrlqlavrerdhderlrdvlsnnealmgmesllrkygleveg 545
QY 131 LCSTLKKQMKYLEEQODETK----QAEAGRLRSKMKMTMEQELLQSQLPVEVE---- 182
DB 546 l-sttcgnlqwlkeem-etkfrwqkeges-----llqqlqtslhdnkevedlsat 595


```

XX  MO200027861-A1.
PN
XX
PD  18-MAY-2000.
XX
XX  12-NOV-1999; 99MO-US26860.
XX
XX  12-NOV-1998; 98US-0108255.
XX
XX  (STRD ) UNIV LELAND STANFORD JUNIOR.
XX
XX  Conti M, Pahlke G;
PI
XX
XX  WPI: 2000-376479/32.
DR  N-PSDB; AAD00769.
XX
XX  Polynucleotide encoding a phosphodiesterase (PDE) interacting
PT  polypeptide, useful for diagnosis and treatment of asthma, cystic
PT  fibrosis, Crohn's disease, and rheumatoid arthritis -
XX
XX  Disclosure; Fig 5; 77pp; English.
PS
XX
XX  The present sequence is a phosphodiesterase (PDE)
CC  interacting protein, myomegalin obtained from two human clones
CC  KIAA0454 and KIAA0477. The myomegalin gene is located on human
CC  chromosome 1p35.1-p36. The protein modulates the functions and properties
CC  of PDEs, specifically cAMP-PDEs, and also targets them to specific
CC  subcellular compartments. The present sequence
CC  can be used in the diagnosis and treatment of disease conditions
CC  associated with PDE activity. The diseases include asthma, cystic
CC  fibrosis, inflammatory airway disease, chronic bronchitis, eosinophilic
CC  granuloma, psoriasis, proliferative skin diseases, endotoxic shock,
CC  septic shock, ulcerative colitis, Crohn's disease, reperfusion injury,
CC  inflammatory arthritis, atopic dermatitis, urticaria, adult respiratory
CC  distress syndrome, diabetes insipidus, allergic rhinitis, allergic
CC  conjunctivitis, vernal conjunctivitis, arterial restenosis,
CC  atherosclerosis, inflammatory diseases associated with irritation and
CC  pain, rheumatoid arthritis, ankylosing spondylitis, transplant
CC  rejection and graft versus host disease, disease conditions associated
CC  with hypersecretion of gastric acid, and disease conditions in which
CC  cytokines are mediators.
XX
XX  Sequence 2517 AA;
SQ

```

```

Query Match 7.08; Score 167.5; DB 21; Length 2517;
Best Local Similarity 22.8%; Pred. No. 0.00031;
Matches 91; Conservative 82; Mismatches 139; Indels 87; Gaps 21;

```

```

QY  24 HCGHTF-HLQCLIOSEFTAPSRPCPOCRIOYGRKTIINKLFFDLAQEEENYLDREF-LKN 81
DB  601 hlnshshkqellqef-----rellygrdnscdkleaneml--lektrqthdkavaler 653
QY  82 ELDNVRAQLSQDKERKDSQVYI-----DTRLRDTLEERNATVVSQOALG---KAEM 130
DB  654 aieekfsaleekelqqlavrerhdlerldvlsneatqsmesllrakgleveq 713
QY  131 LCSTLKRQMKYLEQOODETK---QAOEBAGRLSKMKMTMEQILLLQSLPEVEB--- 182
DB  714 l-stcqlnqlwikeem-etkfsrwkqegs-----llqqlqtslhdrrkvedlsat 763
QY  183 MIRMVGSGASV-ROLAVVYCSLKKEVENLKEARKKASGEVADKRLKLFSSRSK----- 235
DB  764 lcklqrgseiaeel---cgrlqtk-----emhldqlldsrnkqvlehe 805
QY  236 -----IQTVYSELDAQLELSAQKDLQSADEKIMSLKKLTMLOETLNPVPASSETVD 289
DB  806 melgllqsvstrgesqaaeklvqalmernselqalrqlggrdsimsqaplsnqgae 865
QY  290 -----RLVESPAVEVNLKLRPSFRDDIDLNAFTVDVPPARPSSQHGYYKLC-LF 343
DB  866 vtpgrlqgktdgg-----smqjpsrddstslakedsip-----xstlqldltvagle 915

```

```

QY  344 KSHSPIQDVPKKICKGPRKESQSLSG-OSCAQEPDEEL 381
DB  916 kelsnakeelelnakker-esgmelsalqsmavgeeel 953

```

```

RESULT 22
ABB71396
ID  ABB71396 standard; Protein: 482 AA.
XX
XX  ABB71396;
AC
XX
XX  26-MAR-2002 (First entry)
DT
XX
XX  Drosophila melanogaster polypeptide SEQ ID NO 40980.
DE
XX
XX  Drosophila; developmental biology; cell signalling; insecticide;
KW  pharmaceutical.
XX
XX  Drosophila melanogaster.
OS
XX
XX  WO200171042-A2.
PN
XX
XX  27-SEP-2001.
PD
XX
XX  23-MAR-2001; 2001MO-US09231.
PF
XX
XX  23-MAR-2000; 2000US-191637P.
PR
XX  11-JUL-2000; 2000US-0614150.
PA
XX  (PEKE ) PE CORP NY.
PI
XX  Venter JC, Adams M, Li PWD, Myers EW;
XX  WPI, 2001-656860/75.
DR  N-PSDB; ABL15499.
XX
XX  New isolated nucleic acid detection reagent for detecting 1000 or more
PT  genes from Drosophila and for elucidating cell signalling and cell-cell
PT  interactions -
XX
XX  Disclosure; SEQ ID NO 40980; 21pp + Sequence Listing; English.
PS
XX
XX  The invention relates to an isolated nucleic acid detection reagent
CC  capable of detecting 1000 or more genes from Drosophila. The invention is
CC  useful in developmental biology and in elucidating cell signalling and
CC  cell-cell interactions in higher eukaryotes for the development of
CC  insecticides, therapeutics and pharmaceutical drugs. The invention
CC  discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC  sequences (ABL01840-ABL16175) and the encoded proteins
CC  (ABB5737-ABB72072).
CC  The sequence data for this patent did not form part of the printed
CC  specification, but was obtained in electronic format directly from WIPO
CC  at ftp.wipo.int/pub/published_pcl_sequences.
XX
XX  Sequence 482 AA;
SQ

```

```

Query Match 7.08; Score 167; DB 22; Length 482;
Best Local Similarity 20.8%; Pred. No. 3.4e-05;
Matches 74; Conservative 59; Mismatches 101; Indels 122; Gaps 14;

```

```

QY  7 CTICSDPFDSRD-VAAIHGHTFHLQCLIOSEFTAPSRPCPOCR----- 50
DB  175 cpyclermdesvdvylclhahascilmkwdg----tcpyvrhvcqtpglvedsvcmc 230
QY  51 -----IQGKRTIINKLFFDLAQEEEN 72
DB  231 ceptdswicligcgvqgrvggaaahfratnhtfamqgtasv-----wdya--gdn 283
QY  73 VLDRFLKNELDNVRAQLSQDKERKDSQVYIITLRLPTLEERNATVVSLOQALGAEMLC 132
DB  284 fvhlrf-gnksgd-gklvasgtekereeki-----dsmg-----meflyllt 323

```


CC Immunogenic protein is useful for preventing, reducing or ameliorating
 CC Blomia tropicalis hypersensitivity condition such as atopic dermatitis,
 CC immediate hypersensitivity, systemic anaphylaxis, allergic rhinitis or
 CC asthma and for modulating an immune response directed to Bt allergen in
 CC a subject. The Bt allergens are also useful for detecting antibody
 CC directed to all or a part of Bt allergen in a biological sample from a
 CC subject. Antibodies to Bt allergens are also used as therapeutic or
 CC diagnostic agents, to screen Bt immunoassays and as antagonists to
 CC inhibit Bt activity under circumstances where temporary hypersensitivity
 CC inhibition is required. The present sequence is Bt11 allergen.

XX Sequence 875 AA:

Query Match 7.0%; Score 166.5; DB 22; Length 875;
 Best Local Similarity 22.8%; Pred. No. 8.7e-05;

Matches 64; Conservative 60; Mismatches 74; Indels 83; Gaps 11;

QY 66 LAQEEENVLD--REFLNKELDN---VRAQLSQ-----KDKERKDS-----QV 102
 Db 204 lsgensellkevhney-kisidnanhlkqgiagqledrhrledeerksslenhahle 262
 QY 103 IITLRLTLEERNATVSVLQALGKA----- 128
 Db 263 elsesllkvqleeeseaerleerqltkangdaaswkskyaeelqahvdeveelrrkmaqkis 322
 QY 129 ---EML-----CSTLKQKKKYLEQOOD---ETKQAOEAGRLRSKMKTMEQTELLLOS 175
 Db 323 eyegedleallnkcsalekqkarlqsevevlimdekatahagalekqvsgleklnldlks 382
 QY 176 QLPVEEEMIRDMGVGSABQLAVYCVSLKK---EYENLKEARKASGEVADKLKDLFSS 232
 Db 383 klevsmll-----egtgdlrvkiadlqklqheyecklrdqkealarenkkladiadae 436
 QY 233 RSKLQIVYSELDAQKLELK---SAQKDLQASADKEIMSLKK 270
 Db 437 ksqldahrrihgeleikrlenereelaayaakeaelrlrkq 477

RESULT 25

AAE02242
 ID AAE02242 standard; Protein; 878 AA.

XX AAE02242;

XX 31-JUL-2001 (first entry)

XX Domestic mite Bt11 allergen #7.

XX Mite; immunogenic protein; Bt allergen; therapy; atopic dermatitis;

XX immediate hypersensitivity; systemic anaphylaxis; allergic rhinitis;

XX asthma; antiallergic; antiinflammatory; immunosuppressive.

XX Blomia tropicalis.

XX WO200130817-A1.

XX 03-MAY-2001.

XX 10-OCT-2000; 2000WO-AU01227.

XX 26-OCT-1999; 99SG-000513.

XX 18-JUL-2000; 2000AU-0008842.

XX 18-JUL-2000; 2000AU-0008844.

XX 18-JUL-2000; 2000AU-0008845.

XX (UYSI-) UNIV SINGAPORE NAT.

XX Chua KY, Cheong N, Lee BW;
 XX WPI, 2001-308609/32.
 XX DR N-PSDB; AAD06236.
 XX

PT Novel immunogenic protein derived from house mite, Blomia tropicalis
 PT useful for treating and diagnosing conditions involving induction of
 PT immuneresponse to mite, such as allergic asthma, atopic dermatitis,
 PT rhinitis -

XX Claim 4: Fig 3; 230pp; English.

XX The present invention relates to immunogenic proteins, referred as Bt
 CC allergen, is derived from domestic mite, Blomia tropicalis. The specific
 CC Bt allergens of the invention includes Bt11, Bt10, Bt5 and BtA2. The
 CC immunogenic protein is useful for preventing, reducing or ameliorating
 CC Blomia tropicalis hypersensitivity condition such as atopic dermatitis,
 CC immediate hypersensitivity, systemic anaphylaxis, allergic rhinitis or
 CC asthma and for modulating an immune response directed to Bt allergen in
 CC a subject. The Bt allergens are also useful for detecting antibody
 CC directed to all or a part of Bt allergen in a biological sample from a
 CC subject. Antibodies to Bt allergens are also used as therapeutic or
 CC diagnostic agents, to screen Bt immunoassays and as antagonists to
 CC inhibit Bt activity under circumstances where temporary hypersensitivity
 CC inhibition is required. The present sequence is Bt11 allergen.

XX Sequence 878 AA:

Query Match 7.0%; Score 166.5; DB 22; Length 878;
 Best Local Similarity 22.8%; Pred. No. 8.7e-05;

Matches 64; Conservative 60; Mismatches 74; Indels 83; Gaps 11;

QY 66 LAQEEENVLD--REFLNKELDN---VRAQLSQ-----KDKERKDS-----QV 102
 Db 207 lsgensellkevhney-kisidnanhlkqgiagqledrhrledeerksslenhahle 265
 QY 103 IITLRLTLEERNATVSVLQALGKA----- 128
 Db 266 elsesllkvqleeeseaerleerqltkangdaaswkskyaeelqahvdeveelrrkmaqkis 325
 QY 129 ---EML-----CSTLKQKKKYLEQOOD---ETKQAOEAGRLRSKMKTMEQTELLLOS 175
 Db 326 eyegedleallnkcsalekqkarlqsevevlimdekatahagalekqvsgleklnldlks 385
 QY 176 QLPVEEEMIRDMGVGSABQLAVYCVSLKK---EYENLKEARKASGEVADKLKDLFSS 232
 Db 386 klevsmll-----egtgdlrvkiadlqklqheyecklrdqkealarenkkladiadae 439
 QY 233 RSKLQIVYSELDAQKLELK---SAQKDLQASADKEIMSLKK 270
 Db 440 ksqldahrrihgeleikrlenereelaayaakeaelrlrkq 480

RESULT 26

AAW78854
 ID AAW78854 standard; Protein; 1960 AA.

XX AAW78854;

XX 06-NOV-2001 (first entry)

XX Human protein SEQ ID NO 1516.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;

XX KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;

XX KW tissue growth factor; immunomodulatory; cancer; leukaemia;

XX KW nervous system disorder; arthritis; inflammation.

XX Homo sapiens.

XX WO200157190-A2.

XX 09-AUG-2001.

XX 05-FEB-2001; 2001WO-US04098.
 XX 03-FEB-2000; 2000US-0496914.

Db 1155 elkmqlakke--eelgaalarveeaaqkmalikkirelesqiselqedleserasnka 1212
 QY 94 DKRRSQVIIDRLRDLERNTATVSLQALAKAE---MLCSTLKQKVKYLEQQODER 149
 Db 1213 ekxkridgeelakleledtdstaagqlrskrqevnllkklleeaaktheaqigem 1272
 QY 150 KOQOEBA-----GRLRSKMTME-----QIELLLOS-----QLPEV 180
 Db 1273 rghhsqaveelaegqlkrvkanlekaqgtlennergelanevkvllqgqgdsenhkrkv 1332
 QY 181 EEMIRDMGV---GQSAVEQLAVYCVSLKKEVYENLKEARRASGEVADKLKRDLFSSRSKL 236
 Db 1333 eaqlgelqyvfneqervrteladkvtkllygelndvltgllsqdsksakslkdkfsalesqj 1392
 QY 237 QTVYSELDOAKLELKSQKLOLSADKEIMSLKKTMLMLOETLMLPPVASTVDRIVLESP 236
 Db 1393 q-----dtgelllgeenrgklsistklkqvvedekn----- 1421
 QY 297 APVEVNLKLRPSFRDDIDNATFDVTPPARPSSQHGYYEKLCLEKS---HSPIDOV 332
 Db 1422 -----sfregle-----eeeeakhn-----lekqiatlhagayadm 1451
 QY 353 PKRI-----CKGPRKESQSLSGQSCAGPDEELVGAFPIFYNNAILGQKQ---- 398
 Db 1452 kkkmedsvgclataeevkrklqkdlegls---qrheekvaaykklkctkrlqgelddl 1508
 QY 399 -PKRPRESSCSKDVATGFDGIGGRKFI 427
 Db 1509 vdlhdqrgsacnlekqkktfdqllaeeKtl 1538

RESULT 28

AA01632
 ID AA01632 standard; Protein; 2954 AA.

AA01632;

22-JUN-1999 (first entry)

DE Amino acid sequence of centromere-associated protein-E (CENP-E).

XX CENP-E; centromere-associated protein-E; ATPase activity;
 KW plus end-directed microtubule motor activity; chromosome congression;
 KW microtubule binding activity; chromosome movement; mitosis;
 KW cell proliferation; tumor; metastasis; vascular malfunction;
 KW inflammatory disease; immune disease; angiogenesis; hypertension;
 KW restenosis; fungal infection; selective herbicide; fungicide;
 KW insecticide; plant growth regulator; activator; cancer cell marker.

XX Xenopus sp.

OS W09913061-A1.

PN 18-MAR-1999.

PD 10-SEP-1998; 98WO-US19231.

PF 11-SEP-1997; 97US-0058645.

PR (REGC) UNIV CALIFORNIA.

PA Cleveland DW, Goldstein LSB, Sakowicz R, Wood KW;

PI WPI; 1999-229233/19.

DR N-PSDB; AAX26819.

XX Centromere-associated protein-E and related nucleic acid

PS Claim 5; Page 66-67; 77pp; English.

CC The present sequence represents CENP-E (centromere-associated protein-E)
 CC of Xenopus. The protein has at least one of plus end-directed microtubule
 CC motor activity, Arpase (adenosine triphosphatase) activity and

CC microtubule binding activity. CENP-E is the motor that powers chromosome
 CC movement toward microtubule plus ends and is essential for congression
 CC of chromosomes during mitosis. Modulators of CENP-E can thus control
 CC cell proliferation. Agents that modulate CENP-E activity are lead
 CC therapeutic, bioagricultural and diagnostic agents, e.g. for treatment
 CC of unwanted cell proliferation (typical of many examples are tumors and
 CC metastases); vascular malfunction; inflammatory and immune diseases;
 CC angiogenesis; hypertension; restenosis; and fungal infections), also as
 CC plant-protection agents (selective herbicides, fungicides and
 CC insecticides) and plant growth regulators or activators for improving
 CC yields. CENP-E is also a diagnostic marker for dividing cells, including
 CC cancer cells.

SO Sequence 2954 AA;

Query Match 6.9%; Score 165.5; DB 20; Length 2954;
 Best Local Similarity 21.4%; Pred. No. 0.00057;
 Matches 82; Conservative 68; Mismatches 127; Indels 107; Gaps 15;

QY 34 LIOSEFAPSPRTQPCRIQVGKRT-----ITKKLFEDLAQEENYLDREFLK 80
 Db 1584 laknlataasnpc---ltqeketsadcvhpleeKlllleelhqktneqekllhe---k 1637
 QY 81 NELDNVRAQLSOKDKERDSQVIIDRLRDLERNTATVSLQALAKAEMLCSTLKQK 140
 Db 1638 nelegaqvelkce-----vehlmksmiesksleslqnekhdteqllalqgmq 1687
 QY 141 YLEQQODETKOAE---EAGRLRSKM-----KTMEQIETL 172
 Db 1688 vltqekkelqgthnehltlaevdhlnkenlelglnfneaqgktkegcclnnekelegqhr 1747
 QY 173 LOSQLPEVEEMIRDMGVGQSAVEQL---AVYCVSLK-----EYNNLEAKRASEVA 222
 Db 1748 lqc---eleelmkslkdkesqkvlnlqgemvmv]emlelnsqftvaier 1804
 QY 223 DKLRDLFSSRSKIQTVYSELDOAKLELSAOKDLOGSADKEIMSLKKTMLMLOETLMLPP 282
 Db 1805 dqlqgddl---resvemsietqg---dlrkagelqgqkavqelstqslvqekisl-- 1855
 QY 283 VASETVDRILYESPAVEVNLKLRPSFRDDIDNATFDVTPPARPSSQHGYYE--- 338
 Db 1856 -----lenqmlynvatkeltl---serddln-----gskqhlfseietl 1891
 QY 339 KLCLEKSHSPIDOVPKKIGKPRK 362
 Db 1892 slsikefalegaekkadaarK 1915

RESULT 29

AA080122

ID AAM80122 standard; Protein; 690 AA.

AC AAM80122;

DT 06-NOV-2001 (first entry)

DE Human protein SEQ ID NO 3768.

XX Human; cytokine; cell proliferation; cell differentiation; gene therapy;
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;
 KW nervous system disorder; arthritis; inflammation.

OS Homo sapiens.

PN W0200157190-A2.

PD 09-AUG-2001.

PF 05-FEB-2001; 2001WO-US04098.

PR 03-FEB-2000; 2000US-0496914.

PR 27-APR-2000; 2000US-0560875.
 PR 20-JUN-2000; 2000US-0598075.
 PR 19-JUL-2000; 2000US-0620325.
 PR 01-SEP-2000; 2000US-0654936.
 PR 15-SEP-2000; 2000US-0663561.
 PR 20-OCT-2000; 2000US-0693325.
 PR 30-NOV-2000; 2000US-0728422.
 XX
 XX (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
 PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
 PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
 XX
 DR WPI: 2001-476283/51.
 DR N-PSDB; AAK53255.
 XX
 PT Nucleic acids encoding polypeptides with cytokine-like activities,
 PT useful in diagnosis and gene therapy -
 XX
 XX Claim 20; Page 430; 6221pp; English.
 XX
 CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
 CC encoded polypeptides (AAM/8333-AAK60302) that exhibit activity elating to
 CC cytokine, cell proliferation or cell differentiation or which may induce
 CC production of other cytokines in other cell populations. The
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
 CC peptide therapy. The polypeptides have various cytokine-like activities,
 CC e.g. stem cell growth factor activity, haematopoiesis regulating
 CC activity, tissue growth factor activity, immunomodulatory activity and
 CC activity/inhibin activity and may be useful in the diagnosis and/or
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
 CC inflammation.
 CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
 CC (AAM0020) are omitted as the relevant pages from the sequence listing
 CC were missing at the time of publication.
 CC
 XX
 XX Sequence 690 AA;
 SQ
 Query Match 6.9%; Score 164.5; DB 22; Length 690;
 Best Local Similarity 23.3%; Pred. No. 9.1e-05;
 Matches 100; Conservative 64; Mismatches 129; Indels 137; Gaps 20;
 QY 64 FDIAEEENVLDREFL-----KNELDNVRQAOLSKDKERDSQVITDRLDTEERNATV 119
 DB 269 ydkvksrdalegevieirrkheileaslmqtkerselskev-----tlleg---tlvt 319
 QY 120 SLQ---QALGKAEM---LCSTLKKQMKYLEQOODETRKQAE-----AGRLSKMK-- 164
 DB 320 llqdkkeylrrgmelmavrcanehedrlerlqagleskkaeemeykvasrdhykteye 379
 QY 165 -----TMEQJELLQSOLPREVEEMIRDMGVGQSAVEQOLAVYCVSLKKEYLEKAKARASG 219
 DB 380 nklnhdelegirrlktngeldqlrnasrem-----yerenlnleat--dn 421
 QY 220 EVADKLK-----KDL-----FSSRSKLTQTVSE----- 242
 DB 422 aveekeraemaekdalehqqlldryrelqlsteskvtelfngsklksfsfeervqllqee 481
 QY 243 -----LDQAKLELSAOKDLOSADKEIMSL-----KKKLJMTL-----QETLNLPPVASET 287
 DB 482 tarnltcqlcecekygkkllevltkefyslqassekrltelqagqnsehqarldlyekele 541
 QY 288 VDRLVLESPAPVEYNLKLRRPSFRDDIDLNATFDVDTPPAPRSSQGYEKLCKLESKS 347
 DB 542 ldeilmgt-aelenedaeavlilsygyanvp---tlakrrlkqsvhlarvrlqekqns 597
 QY 348 PIDQVPRKIKGPRKESQLSIGGSCAGPEPDEELVGAFFIFVR-----NAILLG-KOPKR 401
 DB 598 li-----lkrsgtskgspsnta-----ftrslteamsllngvtqgpyr 633
 QY 402 PRSSSCSKMD 411

DB 634 ylliesvrgd 643
 II : I
 RESULT 30
 AAB96332
 ID AAB96332 standard; Protein; 880 AA.
 XX
 AC AAB96332;
 XX
 DT 29-OCT-2001 (first entry)
 XX
 DE Putative P. abyssi Arpase involved in DNA repair #2.
 XX
 KM Hyperthermophilic archaeon; hyperthermophilic protein.
 XX
 OS Pyrococcus abyssi.
 XX
 PN FR2792651-A1.
 XX
 PD 27-OCT-2000.
 XX
 PF 21-APR-1999; 99FR-0005034.
 XX
 PR 21-APR-1999; 99FR-0005034.
 XX
 PA (CNRS) CNRS CENT NAT RECH SCI.
 (IFRE-) IFREMER INST FR RECH EXPL MER.
 PI Forterre P, Thierry JC, Prieur D, Dietrich J, Lecompte O;
 PI Querellou J, Weissenbach J, Saurin W, Hellig R;
 XX
 DR WPI: 2001-126236/14.
 XX
 PT New nucleotide sequences isolated from Pyrococcus abyssi encode
 PT proteins useful in industry -
 XX
 XX Claim 7; Pages 1003-1006; 1657pp; French.
 XX
 CC The present invention relates to the genomic sequence of Pyrococcus
 CC abyssi (see AAB96431 and AAB91223-7) and P. abyssi proteins. P. abyssi is
 CC a hyperthermophilic archaeon, which is isolated from deep-sea
 CC hydrothermal vents. The present sequence is one such P. abyssi protein.
 CC The proteins of the present invention have various potential industrial
 CC uses, since the proteins are stable at very high temperatures, some up to
 CC 110 degrees centigrade.
 CC Note: This patent is in the same patent family as WO2000065062, which
 CC contains additional sequences as shown in AAB99132-AAB99143,
 CC AAB75903-AAB75920 and AAG66436.
 CC
 XX
 XX Sequence 880 AA;
 SQ
 Query Match 6.9%; Score 164.5; DB 22; Length 880;
 Best Local Similarity 21.9%; Pred. No. 0.00013;
 Matches 61; Conservative 65; Mismatches 122; Indels 31; Gaps 7;
 QY 65 DLAOEEENVLDREFLKNELDNVRAOLSKDKERDSQVITDRLDTEERNATVSLQQA 124
 DB 226 elekvrenvkelssikqklselklyqeklkgrkgleekltvgdrtersleekakiseleel 285
 QY 125 LGAEMILCSTLKKQMK---YLEQOODETRKQAEAGRLRSKMKMTMEQIEILLQSOLPREVE 181
 DB 286 vkdlprkgekeyrkikgfrdeyeshlrrlelelkswelekaieevlkegekkerae 345
 QY 182 EMIRDMGVGQSAVEQOLAVYCVSL-----KKEYLEKAKR--ASGEVADKL-----RK 227
 DB 346 efreklselkrelleeklyveeledakvqgkqierlkarlqglspgveilekleslekert 405
 QY 228 DLFSRSKLTQTVSELDQALLELSAOKDQSA-----DKETMSLKKRLTMTQETLNL 280
 DB 406 elealelkeltrlgmqekqnermkaleelrkkakgkpcvsgrelteehkkelmerylel 465

Yr	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710
----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

```

Dd      321 hnev1kes1-takeqraa1lqrevad1r1rleeke5f1nkkctkq1qd1leeqytl1agelr 379
Oy      79 -----1:KNELDVNR40LSQDKDEKRD5QV1ID1RLPTLEERNATVVS1LOQ 123
Dd      380 dmkkm1evker1inv1qkkien1lge1lrkdkq1t1nk1krvslq1cdsntd1a1t1lee 439
Oy      124 ALGKAEMLCSTLKQKQK1VEEQ00DETKQAOEAGRLRSKMTWEO1ELLQ5OLPEVEEK 183
Dd      440 a1seker1ier1ik-----egredrre1lee1es1fir1kenk1d1ikevna1lqae1lekes 493
Oy      164 IRDMCVGS-----ANEQ1AVYCVSLK---KEVENLKAEAKKASGEVA 222
Dd      494 11d1kehass1lasag1kr1dsk1ks1e1a1e1eq1keesk1leaq1kkahn1led1armpe1fa 553
Oy      223 DKLR---KDLFSSRSK1QTVYSELDOAKLELKSAQKDLQ5ADK5E1MSLKKT1MLQETLN 279
Dd      554 dq1kq1dkeas1yrrdeeq1agae1vdt1l1e1l1keve1ekndk1d1e1e1t1lr1mk1dqn 613
Oy      280 LPPVASETVDR1LVLESAPAEVNLKLRPSFRDD1D-----LNA---TPDVDP1PPAR 328
Dd      614 kkvaa1khng1eq1ekkn1naq1leevrrred1sma1d1nq1lq1eelma1e1ktr1gel1datkar 673
Oy      329 PSSSQHGYEK 339
Dd      674 lastqslae1k 684

RESULTE 32
AAB96721
ID      AAB96721 standard; Protein; 1177 AA.
AC      AAB96721;
XX      29-OCT-2001 (first entry)
DE      Putative P. abyssi ATPase involved in DNA repair #3.
XX      Hyperthermophilic archaeon; hyperthermophilic protein.
XX      Pyrococcus abyssi.
OS      Pyrococcus abyssi.
XX      FR2792651-A1.
XX      27-OCT-2000.
PD      21-APR-1999; 99FR-0005034.
XX      21-APR-1999; 99FR-0005034.
XX      21-APR-1999; 99FR-0005034.
XX      (CNRS ) CNRS CENT NAT RECH SCI.
PA      (IFREMER) IFREMER INST FR RECH EXPL MER.
XX      Porterre P, Thierry JC, Prieur D, Dietrich J, Lecompte O;
PI      Querellou J, Weissenbach J, Saurin W, Hellig R;
XX      WPI: 2001-126236/14.
DR      110 degrees centigrade.
XX      Note: This patent is in the same patent family as WO2000065062, which
CC      contains additional sequences as shown in AAB99132-AAB99143,
CC      AAH75903-AAH75920 and AAG66436.

```

XX	Sequence	1177	AA;
SQ			

Query Match	6.9%	Score 164;	DB 22;	Length 1177;
Best Local Similarity	21.8%;	Pred. No. 0.00021;		
Matches	73;	Conservative	72;	Mismatches 100;
			Indels	90;
			Gaps	15

```
QY      61 KLFEDLGOEENVLDRELEKLNEDNVAQAQSOKKKERKSQVYIIDTLROTLEERNATVS 120
Dz      178 ka|e|l|kaeeenlarvd||l|re---vkkq|d|k|eeendalryld-l|ke|le|arave||- 232
QY      121 LQALGAKEMCSTLKMKOMKYLEOQOETKOAGE-----NGRLSKKMTMEJELLLOS- 175
Dz      223 ----lgelkkvesekiganderlekleeelkeeleekiseetake|vrkerle|keveelle|ke 288
QY      176 -----OLPVEEEMI-----DDMGVGGSAYVOLWVCVSLKEYEN-LKEARKASGE 220
Dz      289 sseealk|t|re|ge|evnskn|akn|ieva|kkeldeaq|rl|kakdel|k|kv|seleks|gna 348
QY      221 VA-----DKLRKDFFSSRSKIQTYSSELDQ-----AKLELSKAOKMDLOSADEIMS 266
Dz      349 i|arw|kt|re|aalnk|t|-ke|leenrk|lvvk|geidrt|lavareedndnv|klema|rks|ye 407
QY      267 LK---KITLMIOELPLNPVASEFVDVRLVLESAPAEVNILKRPRSRDDIDINAFDVD 323
Dz      408 neadik|t|re|ae|ek|er|s-----srft|t|-----lkakipj|reev----- 440
QY      324 TRPARPSSOHGYEKL--CLEKSHRPIODVPKKI 356
Dz      441 -----ek|lr|ek|leek|kaeel|nveei| 461
```

RESULT 33

ID AAY77575 standard; Protein; 2442 AA.

AC AAY77575;

DT 08-MAY-2000 (first entry)

DE Human cytoskeletal protein (HCYT) (clone 1655208)

KM Human cytoskeletal protein; HCYT; cell proliferation; immunological; reproductive; nervous disorder; cytostatic; immunosuppressive; anti-HIV; anti-diabetic; antiatherosclerotic; dermatological; anti-inflammatory; anti-infertility; vasotropic; cardant.

OS Homo sapiens.

PN WO200006730-A2.

PD 10-FEB-2000.

PF 30-JUL-1999; 99WO-US17167.

PR 31-JUL-1998; 98US-0155185.

PR 19-AUG-1998; 9805-0155228.

PA (INCY-) INCYTE PHARM INC.

PI Bandman O, Tang YT, Yue H, Corley NC, Guegler KJ, Azimzai Y,

XX

DR N-PSDB; AAZ58980.

PT Human cytoskeletal proteins useful for diagnosing, treating preventing

PT nervous disorders

PS Claim 1; Page 71-76; 84pp; English.

XX The invention provides human cytoskeletal proteins (HCRYT) and nucleic
CC

SQ **Sequence** **2442 AA;**

Query Match	6.98;	Score 164;	DB 21;	Length 2442;
Best Local Similarity	22.68;	Pred. No. 0.00058;		
Matches 90; Conservative	59;	Mismatches 151;	Indels 98;	Gaps 16;

```

OY 68 QEEENVAIDREFLK--NELDNVRAOLSOJKBERKSDOVIITDLRPLLENNATVAISLOAL 125
Db 863 ekerswhqjelaKalesIereKemelrIkqgctemeaiPaqre--eetqgaesal----- 916

OY 126 GKAEMLCSTLKQKMYLE---QOODETKOQOEAGRLRURSKMTMEIEL---LLOLSLP 178
Db 917 --cqmqjeteKersyIleltlIqtqKelaadsqgIerIdrnmKvqrlKqetgtIltqIq 974

OY 179 EVEEMIR-----DKVGQSAVEOLAVYCYSLKREYNLK-----EARKASGEVA 222
Db 975 eaqgrelKeaarhrdIdlaaIqeesssllqdkmIdIqYvedIksqIvaqdsqgrIvegeVq 1034

OY 223 DKLR-----KIDFSSRSKIQTYYSLEIDOKL-----ELKSADKIDQSDK 262
Db 1035 ekIreCqeynrIqIereKasItIsImeqgIlIvIgaedsIrqgeIsalrIqdmqeaq 1094

OY 263 EIMSLKRLTLMLOETLNPVASEYFVDRULESPAVEY----- 301
Db 1095 eqKelsaqmellIq-----evKekedfIaqeqqIleelIeaahIceqqlrasIvaqeka 1149

OY 302 -NLKRRPSFRDDIDLNATFDVTPPARBSSOHGYEKLCLEKSHPIQDVPRKICKGP 360
Db 1150 aqhlIrIrtscsqleaIa--aeqgpnqdaq-----aqIasIysalqqlsgvce-- 1198

OY 361 RKESQLSLGGQSCAG-----PPDEELVGARPIYPRNAIL 394
Db 1199 -srpeIsqggdsapsvwqIedpqn--garsIktIrpIl 1233

```

RESULT 3

ID AAP90955 standard; protein; 441 AA.

AAP90955;

DT 23-FEB-1990 (first entry)

DE M6 streptococcal protein.

Immunoglobulin.

Streptococcus group A.

FH	Key	Location/Qualifiers
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

FT	Region	248. .269
----	--------	-----------

XX

XX

XX 7

XX

2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526

QY	330	SSSSHGYYRKLLKLEKSHSP1QDVPKTKICKGPKRKESQSLSGGSCAGEPDEELVGAFTIV	389
Db	376	gn-----kvvpqkfgqgpaqgatkpnqkpkmketkrql--pslget-----anpfft	419
QY	390	RNAI 393	
Db	420	aaal 423	
RESULT	36		
AAW08927			
ID	AAW08927	standard; Protein; 483 AA.	
AC	AAW08927;		
XX			
DT	31-MAR-1997	(first entry)	
XX			
DE	Type-6 M-protein.		
XX			
KM	Type-6 M-protein; emm6 gene; Streptococcus pyogenes; signal peptide;		
KM	anchor peptide; C-terminal sorting signal; surface display;		
KM	fusion protein; protease-deficient; Streptococcus gordonii;		
KM	SPEX vector; fusion protein cleavage; spacer; protein secretion;		
KM	TEV-Nia protease; diagnostic; recombinant vaccine; therapy.		
XX			
OS	Streptococcus pyogenes.		
XX			
FH	Key	Location/Qualifiers	
FT	Peptide	1..42	
FT		/note= "Signal peptide (claim 22)"	
FT	Peptide	1..58	
FT		/note= "Preferred N-terminal secretion sequence (claim 23)"	
FT	Peptide	263..342	
FT		/note= "Preferred spacer peptide (claim 32)"	
FT	Peptide	344..483	
FT		/note= "Preferred C-terminal anchoring sequence (claim 25)"	
FT	Domain	405..458	
FT		/note= "Proline/glycine-rich cell wall domain"	
FT	Peptide	449..454	
FT		/note= "Conserved C-terminal motif (AAW08924, claim 9)"	
FT	Domain	459..477	
FT		/note= "Hydrophobic membrane-spanning domain"	
FT	Domain	478..483	
FT		/note= "C-terminal charged tail"	
PN	WO9640943-A1.		
PD	19-DEC-1996.		
PF	06-JUN-1996;	96WO-US09965.	
PR	07-JUN-1995;	95US-0472244.	
PA	(UYRQ) UNIV ROCKEFELLER.		
PI	Darzins A, Hrudy D, Whitehead S;		
DR	WPI; 1997-052336/05.		
DR	N-PSDB; AAT49317.		
PT	Expressing heterologous proteins in gram-positive bacteria -		
PT	cell produces proteins anchored to host's cell surface, or secreted from		
PS	cell		
PS	Disclosure: Fig 3; 41pp; English.		
CC	This sequence represents Streptococcus pyogenes type-6 M-protein,		
CC	which is a cell wall surface protein. The N-terminal signal		
CC	peptide, part of the mature N-terminal sequence, the C-terminal		
CC	sorting signal (anchor) sequence and optionally a spacer region		

CC	from the protein may be expressed as a fusion with a target protein
CC	in a protease-deficient Gram-positive host, e.g. the human oral
CC	commensal <i>Streptococcus gordonii</i> , in a new cloning method involving
CC	the SPK vector series (e.g. plasmid pSPKEX1). The C-terminal
CC	sorting signal contains a proline/glycine-rich region (with a
CC	conserved cell wall anchoring motif AAM08924), a hydrophobic
CC	membrane-spanning region and a charged tail. The resulting fusion
CC	protein is expressed on the cell surface, and may be cleaved with
CC	e.g. tobacco-etch virus TEV-N1A protease (at a site adjacent to the
CC	anchor, e.g. AAM08925-26) for simple purification. A spacer region
CC	from M-protein may be included to reduce steric hindrance during
CC	fusion protein cleavage. A vector without the anchor sequence may
CC	be used for protein secretion. The method may be used in production
CC	of recombinant diagnostic, vaccine and therapeutic proteins.
CC	
XX	
SQ	Sequence 483 AA:
Query Match	6.9%; Score 103.5; DB 18; Length 483;
Best Local Similarity	22.3%; Pred. No. 6.7e-05;
Matches	81; Conservative 70; Mismatches 124; Indels 89; Gaps 14;
QY	55 KRRTINKLPEDLAQEEENVLDREPIKNELDNVRAGLSOKDK--EKRD50VIIDTLRDTLE 112
DB	166 KRLDEYVDKIAKEGSESKEITGLTKKLDE-----LVKDKIAKEGSESKEITGLTKKLDE 220
QY	113 ERNATVSVLQALGKAEMLCSTLKKOMKYLEEODET-----KQAEENGRLSRMK 164
DB	221 ELVKDKIAKEG---ESKEITGLTKKL-----DETVKDKIARQKESQDGLAKG--- 267
QY	165 TWEQIEELLQSLPEVEE-----MTRDNGVGSAAVEQIALVCSLKKEYEINKERKASG 219
DB	268 -----ELAKKDGNGKVSSEASRGIYRRDLDSFEAKKQYVEKDLAINTAEIDKVKKEEQISLD 322
QY	220 EVADDLKRLKDFSSRSKLQTVSELDQAKLEKESAAQKDLQSDAPKELMSLKKRTMLOETLN 279
DB	323 ASRGITRRDLDSR-----EAK--KQVEKALEEANSKIAALEKINKELES-- 366
QY	280 LRPVASETVDRILVLESPAPVEVNLKRLRSPFDDIDLNA-----TFDVPDPARP 329
DB	367 -----KITEKEKELGAKLAEAKALNEGLAKGAEELAKIRAGKAASGQDPAKP 417
QY	330 SSSQHGYYEKKLCLEKSSHPIDVPKIKCGPKKESQSLSGGSCAGEPDEELVGAPITFV 389
DB	418 GN-----KVPYKQGPQAGTCKPNQKAPMKCEKTRQL---PSLGET-----ANPFTT 461
QY	390 RNAI 393
DB	462 AAAL 465
RESULT 37	
AAM40016	
ID	AAM40016 standard; Protein: 1213 AA.
XX	
AC	AAM40016;
XX	
DT	22-OCT-2001 (first entry)
XX	
DE	Human polypeptide SEQ ID NO 3161.
XX	
KW	Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW	peripheral nervous system; neuropathy; central nervous system; CNS;
KW	Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW	amyotrophic lateral sclerosis; Shy-Drager Syndrome; Chemotactic;
KW	chemokine; thrombolytic; drug screening; arthritis; inflammation;
XX	leukemia.
XX	
OS	Homo sapiens.
XX	
PN	WO200153312-A1.
XX	
PD	26-JUL-2001.


```
XX 26-DEC-2000; 2000MO-US34263.
PF
XX
PR 21-JAN-2000; 2000US-0488725.
PR 23-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YF, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodfich R, Drmanac RT;
XX
DR WPI: 2001-442253/47.
XX N-PSDB: AA159172.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
XX such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 3161; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AA157798-AA161369) and
CC the encoded polypeptides (AA38642-AA44213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localized neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 1213 AA;
XX
Query Match 6.9%; Score 163.5; DB 22; Length 1213;
Best Local Similarity 23.5%; Pred. No. 0.00024;
Matches 109; Conservative 70; Mismatches 170; Indels 115; Gaps 20;
QY 39 ETAPSTCPCQCRIOGKRT-IINKL--FPDLAOGEEENVLDREFLNELDNVRAQLSOKRK 95
DB 173 echrttyvlenekhhhdymkksddfnllgeq-----relikl1lgeqekaygarke 227
QY 96 E--KRDQSVIIDLRTPLEERNATVVSLOQALGKAEMLCSTLKQKKVLEOQODEFKQAO 153
DB 228 enakr-----lnklrdelykklksfalm-----vdergmhlegqigls---qkvdqlgkrlr 276
QY 154 EAGRLRS-KMKTMEQIELLQSOL-----PEVEEMIRDMGVGSAVEQALAVCY 202
DB 277 eeeekikaitkskedrgkl1lklevdfenkafrsfsgheemaklangeshnrglrlk1v 336
QY 203 SLKKEVENKKEARK-----ASGEV-----ADKLRRDIFSS----- 232
DB 337 gltqrteeleenunklqkeeeelqelrdk1akgecgsslmaveenllfrvlemegkdee 396
QY 233 -----RSKLQTVVSELDOAKLELSAQKDSADK-EIMSLIKKLTMLQETLNL 280
DB 397 lkttesqcelrltklqgeehshkelrlevexlqkmselxleatskssectqlhnl 456
QY 281 PPVASTVDRL-----VLESFAP-----VEVNLKLRPSPFRDDIDLNAFPVDVPPARPSS 332
DB 457 ekeknltkdl1nelevvksrvkelesesrlekaelslkdldtklksftvm1vderkn-- 514
```

```
QY 333 QHGVEYKLCLEK-----SHSPIDQVPRKICKGPRK-----ESOLSGGSCAGE 376
DB 515 ---mmekikgeerkydglnkfkvegkyvmvteklieskll1lkksmekyynltre 571
QY 377 PDEELVGAFFPFRNALIGOKQKPRRPSRSCSKDVVTRTGEDGL 420
DB 572 rd-ellgkl-----keeksselsescvdl1kkrldgi 603
RESULT 38
ABB59807
ID ABB59807 standard; Protein; 1639 AA.
XX
AC ABB59807;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 6213.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE ) PE CORP NY.
PI Venter JC, Adams M, Li PWD, Myers EW;
PI WPI: 2001-656860/75.
PI N-PSDB: ABL03910.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 6213; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pcc_sequences.
XX
SQ Sequence 1639 AA;
XX
Query Match 6.9%; Score 163.5; DB 22; Length 1639;
Best Local Similarity 21.7%; Pred. No. 0.00036;
Matches 117; Conservative 72; Mismatches 220; Indels 129; Gaps 21;
QY 7 CTRCSDFPHSRDVAIAHGHFFHLQCLIQSFETAPSRTPCQCRIOVGKRTTIINKLFDL 66
DB 1047 clidpcpcylnlvqdaadlnhaklfnlsqtdelartpytrnddele---aklkavgeva1 1103
QY 67 AOEEN-----VIDREFLNELDNVRAQLSOKKREKRDQSVIIDLRTPLEERN 115
DB 1104 agdardnsdgqgtyaevid--lhkhldsvrehlyvsadkfgdangeldrar-----qn 1156
```


• • •